



## PRESS RELEASE

### **AVIZOREX PHARMA, SL receives Notice of Allowance for U.S. Patent on AVX-012 compositions and methods of treatment for Dry Eye Syndrome.**

**Barcelona, March 3<sup>rd</sup>, 2015.** AVIZOREX PHARMA, SL, a Venture Capital backed biopharmaceutical company developing novel therapeutics for Dry Eye Disease, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for compositions and methods of treatment covering AVX-012, a topical treatment for Dry Eye with a new mechanism of action currently undergoing late-stage preclinical studies. The patent to be issued from this allowed application covering an invention from Spanish leading neuroscience center “Instituto de Neurociencias de Alicante” and exclusively licensed to AVIZOREX carries a patent term to at least 2031, and represents a significant addition in AVIZOREX current patent portfolio. The company will continue prosecuting the patent application in other jurisdictions.

“This is a very significant milestone that strengthens our IP position and paves the way to aggressively continue building a solid IP portfolio around our inventions and products in the area of Dry Eye Syndrome”, said Patrick Tresserras, AVIZOREX’s Founder and CEO. “We are looking forward to expanding our patent portfolio as we further investigate the safety and efficacy profile of AVX-012”.

#### **About AVX-012**

Drug candidate AVX-012 significantly increases physiological tear production in chronic Dry Eye animal models without activating ocular nociceptors (pain-mediated tearing) while reduces ocular discomfort associated to dry eye. AVX-012 is well tolerated upon topical ocular administration and is currently undergoing late-stage preclinical studies prior to first-in-human clinical trials.

#### **About AVIZOREX**

AVIZOREX PHARMA, SL is an ophthalmology biotech backed by Inveready Venture Capital with Headquarters in Elche (Alicante, Spain) and offices in Barcelona Science Park, that is developing a new therapeutic target for Dry Eye Syndrome.

The company, a spin-off of Miguel Hernández University, was founded in 2013 on the grounds of neurobiological research performed by the Group on Ocular Sensory Innervation led by Prof. Carlos Belmonte at the Instituto de Neurociencias de Alicante and studies novel pharmacological approaches to treat chronic dry eye.

## CONTACT

Patrick Tresserras

Founder and CEO

AVIZOREX PHARMA, SL

[patrick@avizorex.com](mailto:patrick@avizorex.com)

Tel: (+34) 934029026

[www.avizorex.com](http://www.avizorex.com)